Shares Surge 25% as Q3 Beat and Raised 2026 Outlook Land
TMDX sits 46% above its 52-week low of $60.105 on elevated volume (2.2× avg).
Summary
TransMedics shares jumped more than 25% intraday, the biggest one-day gain since November 2023, after the Q3 print showed revenue of $203M (up 41% year over year) beating consensus by $25.9M and GAAP EPS of $0.46 beating by 12 cents. Operating margin of 13.9% came in 120 bps above Piper Sandler's estimate, and the beat included $9.4M of PAD Aviation charter revenue recognized for the first time after the July strategic investment. The company raised its 2026 revenue outlook to $750M-$760M from $737M-$757M, a smaller bump than the Q3 beat implies, which Piper attributed to potential October softness. Piper reaffirmed Overweight and a $100 target, pointing to an organ retrieval and clinical management service launch in Italy, the Netherlands and Belgium as the next growth driver. Note the Q3 10-Q also disclosed a material weakness in inventory-related internal controls — a risk item that has not derailed the rally but bears watching in the next quarterly filing.
At the time of this announcement, TMDX was trading at $87.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $60.11 to $156.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.